The interaction between alcohol and Empaveli has not been established. However, since alcohol can interfere with some medications, patients are recommended to talk with their healthcare team about the potential effects of alcohol while on Empaveli.
There is a lack of data on the use of Empaveli in pregnant women. Studies in monkeys indicated the treatment may cause harm to the developing fetus. Patients who are pregnant or are planning to become pregnant should discuss this issue with their healthcare providers.
Neither hair loss nor weight gain have been reported in clinical trials as adverse effects associated with Empaveli. Patients are recommended to talk with their healthcare team if they develop any unusual symptoms while on the medication.
Some persons with paroxysmal nocturnal hemoglobinuria (PNH) may see results as early as two weeks after starting treatment with Empaveli. The PRINCE trial showed that, in adults who had never received a complement inhibitor, Empaveli could rapidly lower mean lactate dehydrogenase (LDH) levels within two weeks. LDH is a biomarker of hemolysis, or red blood cell destruction. However, each patient is unique and may respond differently to treatment. Therefore, a discussion with their healthcare team can help PNH patients better understand how Empaveli may help in their particular case.
Empaveli was approved by the U.S. Food and Drug Administration (FDA) in 2021 for use in adults with paroxysmal nocturnal hemoglobinuria (PNH), including those who had never been treated before and those switching from Soliris (eculizumab) and/or Ultomiris (ravulizumab).